Pyrazine-2-carboxamide; pyridine-4-carbohydrazide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Pyrazine-2-carboxamide; pyridine-4-carbohydrazide
• 英文别名: pyrazine-2-carboxamide;pyridine-4-carbohydrazide
• 化学式: C11H12N6O2
• 分子量: 260.25
• InChiKey: BEULNLNSUHHWPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.74
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  137
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• [EN] PREPARATION AND USE OF PSEUDOPTEROXAZOLE AND PSEUDOPTEROSIN ANALOGS AND DERIVATIVES<br/>[FR] PRÉPARATION ET UTILISATION D'ANALOGUES ET DE DÉRIVÉS DE PSEUDOPTÉROXAZOLE ET DE PSEUDOPTÉROSINE
  申请人：NAUTILUS BIOSCIENCES CANADA INC

  公开号：WO2012139212A1

  公开（公告）日：2012-10-18

  New methods of converting pseudopterosins to pseudopteroxazoles have been developed and used to make several new non-natural pseudopteroxazole analogs. These as well as pseudopterosins and derivatives thereof and prenylated aromatic structural mimics of pseudopterosins/pseudopteroxazoles are shown to display anti-bacterial activity including that against non-replicating mycobacteria, with some exhibiting no or limited toxicity against mammalian cells.

  已经开发出将伪角藻素转化为伪角藻恶唑的新方法，并用于制造多种新的非天然伪角藻恶唑类似物。这些物质以及伪角藻素及其衍生物和伪角藻素/伪角藻恶唑的异戊二烯基芳香结构模拟物显示出抗细菌活性，包括对非复制分枝杆菌的活性，其中一些对哺乳动物细胞没有或仅有有限的毒性。
• Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
  申请人：ModernaTX, Inc.

  公开号：US10463751B2

  公开（公告）日：2019-11-05

  The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

  本发明涉及包括编码多肽的多核苷酸的组合物，这些组合物通过用 1-甲基假尿苷取代尿苷进行化学修饰，以改善组织中的一种或多种稳定性和/或清除率、受体摄取和/或动力学、组合物的细胞通路、与翻译机制的啮合、mRNA 半衰期、翻译效率、免疫逃避、蛋白质生产能力、分泌效率、循环通路、蛋白质半衰期和/或细胞状态、功能和/或活性的调节。
• Modified polynucleotides for the production of secreted proteins
  申请人：ModernaTX, Inc.

  公开号：US10703789B2

  公开（公告）日：2020-07-07

  A pharmaceutical composition which has a plurality of lipid nanoparticles that has a mean particle size of between 80 nm and 160 nm and contains a modified mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5′-cap, 5′-UTR, N1-methyl-pseudouridine, a 3′-UTR, and a poly-A region with at least 100 nucleotides.

  一种药物组合物，它具有多个平均粒径在 80 纳米到 160 纳米之间的脂质纳米颗粒，并含有编码多肽的修饰 mRNA。脂质纳米颗粒包括阳离子脂质、中性脂质、胆固醇和 PEG 脂质。mRNA 含有 5′-帽、5′-UTR、N1-甲基假尿苷、3′-UTR 和至少 100 个核苷酸的 poly-A 区域。
• Hepatocurative effect of emblica officinalis against CYP 450 bio-activation hepatotoxicity of drugs
  申请人：——

  公开号：US20030185922A1

  公开（公告）日：2003-10-02

  The present invention relates to a composition useful for hepatocurative effect against CYP 450 bio-activation hepatotoxicity induced by drugs, said composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives and method of treating drug induced hepatotoxicity

  本发明涉及一种对药物诱导的 CYP 450 生物活化肝毒性具有抗肝毒性作用的组合物，所述组合物包含一种从以下植物中提取的提取物 大蒜提取物 和可选的药学上可接受的添加剂，以及治疗药物诱导的肝毒性的方法
• METHOD AND APPARATUS FOR PACKAGING AND DISPENSING PHARMACEUTICALS
  申请人：Apotex Technologies Inc.

  公开号：EP2370043A1

  公开（公告）日：2011-10-05